MGB Biopharma is developing a novel class of anti-infectives based on minor groove binders (MGBs), based on technology developed by Professor Colin Suckling at the University of Strathclyde.
The company has exclusive worldwide licence rights to Strathclyde’s MGB patents for all fields expect anticancer. Minor groove binders have a new mode of action that offers significant advantages over existing anti-infectives, such as being bactericidal and active against a broad range of drug-resistant bacteria.
MGB’s lead drug candidate, MGB-BP-3, is active against key multi-resistant Gram-positive pathogens. The company has developed an oral formulation of MGB-BP-3 for Clostridium difficile that is ready to enter a Phase IIa clinical trial, following the successful completion of a Phase I trial, while an intravenous formulation for a range of Gram-positive infections is in pre-clinical-stage development.
MGB Biopharma announced on 14th March that it has been awarded a £2.78 million grant from Innovate UK, the UK’s Innovation agency, under its Biomedical Catalyst programme. The grant will help fund the Phase IIa trial of the oral formulation of MGB-BP-3. Approximately 30 patients are expected to be enrolled into this multi-centre trial to determine the safety, tolerability, dosing schedule and efficacy of ascending doses of oral MGB-BP-3. Dr Miroslav Ravic, CEO of MGB Biopharma, said “We are delighted that MGB Biopharma has been chosen as one of the recipients of this prestigious award from Innovate UK’s Biomedical Catalyst programme.
The oral formulation of MGB-BP-3 has shown promising efficacy and good safety and tolerability profiles in pre-clinical testing, and in our Phase I trial. The funding provided by this grant from Innovate UK, together with the additional support of our investors, will allow us to initiate this patient trial by the summer of 2018.”
“Despite a renewed interest in developing new antimicrobials, there is still a clear need for truly novel and differentiated products to tackle the growing concern of antimicrobial resistance. We believe that MGB-BP-3’s novel mechanism could, for the first time in over a decade, provide a meaningful breakthrough in the development of antimicrobials for hospital-acquired infections in particular.”
MGB Biopharma was founded in 2010 and is headquartered in Glasgow. It is backed by a number of Scottish investors including Archangel, Barwell, TRI Capital and the Scottish Investment Bank.